Orqis Medical Corporation announced the results of preclinical use of its Exeleras System for chronic heart failure. The system is very similar to the company’s Cancion® CRS™ Cardiac Recovery System, covered by us back in Sept. 2005.
Orqis Medical Corporation… announced that preclinical use of its Exeleras® System led to substantial increases in ejection fraction, reduction in left ventricular dimensions and reduction of left ventricle end diastolic pressure without hemolysis or thrombosis.
The Exeleras System, with an implantable pump about the size of an implantable cardiac defibrillator (ICD), is designed to manage mid- to late-stage chronic heart failure.
The Exeleras®System shares the scientific principles of continuous aortic flow augmentation with the CANCION® System. The Exeleras®System is in development as a fully implantable device with the goal of offering a longer-term option for patients who suffer from chronic congestive heart failure (CHF)…
The Exeleras System is Orqis Medical’s implantable device designed to treat chronic heart failure patients in an ambulatory setting. “It is encouraging to be so close to the next phase of investigation with the Exeleras System given its potential clinical impact,” stated Orqis Medical President and Chief Executive Officer Ken Charhut.
“These data suggest an implantable device may offer significant benefits to heart failure patients and provide an important new therapeutic option,” said Marvin A. Konstam, M.D., Medical Director, Orqis Medical and Chief of Cardiology at Tufts-New England Medical Center. “This approach addresses the underlying disease process and could be a significant advance in treating heart failure.” Orqis expects first clinical implant of the Exeleras System in the first half of next year.